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Objective To explore what triggers an elevated body temperature
of ‡40.0 C in some women given misoprostol, a prostaglandin
E1 analogue, for postpartum haemorrhage (PPH).
Design Post hoc analysis.
Setting One tertiary-level hospital in Quito, Ecuador.
Population A cohort of 58 women with a fever of above 40 C
following treatment with sublingual misoprostol (800 micrograms)
for PPH.
Methods Side effects were documented for 163 Ecuadorian
women given sublingual misoprostol to treat their PPH. Women’s
body temperatures were measured, and if they had a fever of
‡40.0 C, measurements were taken hourly until the fever
subsided. Temperature trends were analysed, and the possible
physiological mechanisms by which postpartum misoprostol
produces a high fever were explored.
Main outcome measures The onset, duration, peak temperatures,
and treatments administered for cases with a high fever.
Results Fifty-eight of 163 women (35.6%) treated with
misoprostol experienced a fever of ‡40.0 C. High fevers followed
a predictable pattern, often preceded by moderate/severe shivering
within 20 minutes of treatment. Body temperatures peaked
1–2 hours post-treatment, and gradually declined over 3 hours.
Fevers were transient and did not lead to any hospitalisation.
Baseline characteristics were comparable among women who did
and did not develop a high fever, except for known previous PPH
and time to placental expulsion.
Conclusions An unexpectedly high rate of elevated body
temperature of ‡40.0 C was documented in Ecuador following
sublingually administered misoprostol. It is unclear why
temperatures ‡40.0 C occurred with a greater frequency in
Ecuador than in other study populations using similar treatment
regimens for PPH. Pharmacogenetic studies may shed further
light on variations in individuals’ responses to misoprostol.
Keywords Fever, hyperpyrexia, misoprostol, postpartum
haemorrhage (PPH).
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Introduction
For decades, researchers have explored the most effective,
safe, and fast-acting pharmacological agents to manage ato-
nic primary postpartum haemorrhage (PPH), a common
cause of excessive bleeding after childbirth. Misoprostol, a
prostaglandin E1 derivative, has been investigated as an
alternative to conventional parenteral uterotonics for PPH
where resources necessary for effective uterotonic (e.g. oxy-
tocin) administration are scarce. Misoprostol is an attrac-
tive alternative because of its uterotonic potency, oral
administration and stability at ambient temperatures.
1,2
Elevated body temperatures of above 40 C, however, have
raised concerns about the safety of this approach.
3–5
The most common side effects associated with the post-
partum administration of misoprostol are shivering and
pyrexia.
6 Studies show the rates of shivering and fever to
be related, and to be dose- and route-dependent.
5–7 Higher
rates of shivering and elevated body temperature are associ-
ated with oral and sublingual routes of administration,
which achieve a higher and quicker maximum plasma con-
centration than vaginal or rectal administration.
7–9 One
trial comparing 600 micrograms oral versus 600 micro-
grams rectal misoprostol conﬁrmed that the oral dose
resulted in signiﬁcantly higher rates of shivering (76 versus
54%) and fever (9 versus 1%).
7 Nevertheless, the reported
rates of shivering and fever vary greatly in the literature.
10
For example, rates of shivering and fever following a
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range from 18 to 71% and from 1 to 38%, respec-
tively.
7,11,12 A review of the literature shows that these side
effects are not severe and are transient, resolving within
12 hours or less.
1,10,13,14
In several PPH prevention and treatment studies,
misoprostol has been associated with fever of above 40 C
(104 F).
12,13,15–19 One case that called the medical commu-
nity’s attention to this ‘rare but alarming complication’
involved a reported peak temperature of 41.9 C following
800 micrograms of oral misoprostol given prophylacti-
cally.
15 Other cases of high fever noted in the literature
include ﬁve of 9198 cases reported from the largest hospi-
tal-based clinical trial on the prevention of PPH, in which
a prophylactic oral dose of 600 micrograms misoprostol
was used.
12 Four cases of 1026 were reported by Ng and
colleagues
13 after testing a similar regimen. A PPH
treatment trial in South Africa reported three women (out
of 114) with temperatures of above 40.0 C following
1000 micrograms misoprostol (200 micrograms orally +
400 micrograms sublingually + 400 micrograms rectally).
16
There have been no other reports of high fever following
rectal administration of misoprostol for PPH.
2,7 In Paki-
stan, a single case of high fever (out of 29) following
adjunct treatment with a sublingual dose of 600 micro-
grams was reported.
17 More recently, two multicentre stud-
ies testing an 800 micrograms regimen of sublingual
misoprostol as ﬁrst-line treatment for PPH reported a
higher-than-expected rate of fever above 40 C in one of
nine sites (36%), whereas much lower rates were recorded
in the other eight sites, ranging from 0 to 9%.
18,19 In all of
these hospital-based reports, the elevated temperatures did
not result in further health complications.
Reports of fever of ‡40.0 C following misoprostol for
PPH have been described on separate occasions as cases of
hyperthermia
15 and severe pyrexia or hyperpyrexia.
5,6,16
These two terms used to describe high fevers actually imply
very different biologic mechanisms. Hyperpyrexia results
from a regulated upward shift in the hypothalamic set point,
which triggers the body to conserve and produce heat to
attain the new set point.
20 In contrast, hyperthermia occurs
when temperature increases in the absence of a shift in hypo-
thalamic set point
21,22: heat conservation measures (e.g. shiv-
ering and seeking warm places) are not induced, and
temperature elevation occurs in an unregulated manner,
making it particularly dangerous. Hyperthermia is relatively
rare compared with hyperpyrexia; nonetheless, what triggers
elevated temperature in some women following misoprostol
administration remains unconﬁrmed.
This manuscript presents a review of high fevers (of
‡40.0 C) occurring at one hospital in Quito, Ecuador, fol-
lowing the administration of 800 micrograms sublingual
misoprostol for PPH treatment. A detailed analysis of the
temperature trends of high fevers that occurred at this high
altitude (2,800 m) site is followed by a discussion of the
possible physiological mechanisms by which postpartum
misoprostol administration produces fever.
Methods
Two large clinical trials were conducted to evaluate the efﬁ-
cacy, safety, and acceptability of sublingual misoprostol
(800 micrograms) as a ﬁrst-line treatment of PPH among
women undergoing vaginal delivery with suspsected uterine
atony.
18,19 The sublingual route was identiﬁed as having
the greatest potential for the treatment of PPH because of
its rapid uptake, long-lasting duration of effect, and great-
est bioavailability, compared with other routes of misopr-
ostol administration.
9 The studies compared misoprostol
with oxytocin using a randomised, double-blind placebo-
controlled non-inferiority study design. In total, 1787
women were treated with one of two regimens: 800 micro-
grams of sublingual misoprostol (n = 895) plus one
ampoule of saline solution or 40 iu of intravenous (IV)
oxytocin (n = 892) plus placebo tablets resembling misopr-
ostol. Providers and women were masked to treatment
assignment. Measured postpartum blood loss, change in
pre- to post-delivery haemoglobin levels, and recourse to
additional interventions beyond the initial study treatment
were documented to assess the efﬁcacy of each uterotonic
therapy. The median blood loss at the time of PPH treat-
ment was 700 ml, and active bleeding was controlled
within 20 minutes with initial study treatment alone for
nine out of ten women treated with misoprostol. Hospitals
from Burkina Faso, Ecuador, Egypt, Turkey, and Vietnam
participated in the clinical research from August 2005 until
January 2008. The study ﬁndings and trial design have been
reported separately.
18,19
The present study is a post hoc analysis of the side effect
proﬁles and the acceptability of secondary effects associated
with misoprostol treatment. Data were collected on the
maternal side effects detected by providers or reported by
women within the ﬁrst 20 minutes of treatment adminis-
tration. Delivery attendants rated the severity (mild, mod-
erate or severe) of any side effect noted, and recorded any
treatment given to manage it. Side effects necessitating
treatment were managed according to each hospital’s clini-
cal protocol. If fever was perceived by women or delivery
attendants, body temperature was then measured with the
standard thermometers routinely used in each centre. At
3 hours postpartum, delivery attendants reassessed the
health status of the women and recorded any side effects
that were experienced since the last observation. Prior to
discharge from the hospital, delivery attendants interviewed
women about the acceptability of side effects following
treatment.
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or excessively frequent side effects, and any serious adverse
events occurring at other sites. An independent Data Safety
and Monitoring Board was established to review reports of
adverse events, provide advice on risk management, and
review interim analyses to ensure the continued scientiﬁc
validity and merit of the study. Regular monitoring and
retraining of the delivery ward staff continued throughout
the duration of the trial. The study protocol was approved
by the Western Institutional Review Board (WIRB) as well
as all relevant local ethics committees.
Following the ﬁrst report of a body temperature of
‡40.0 C, delivery attendants were retrained on how to rec-
ognise, measure, and manage fever. Management practices
for reducing fever included removing blankets from the
patient, applying cool compresses, administering oral acet-
aminophen, and ensuring adequate hydration by mouth or
IV. To capture the details associated with this side effect in
Ecuador, where reports of high fever were most frequent,
delivery attendants were asked to complete an additional
study form to document the onset, duration, peak temper-
atures, and treatment of cases with high fever. When fever
was observed, delivery attendants measured the woman’s
body temperature, and continued to measure her tempera-
ture at a maximum of hourly intervals using an oral mer-
cury thermometer, until the fever subsided (measuring
below 38.0 C). Tympanic and digital oral thermometers
were also used to compare results with the oral mercury
thermometer.
These additional study forms were entered into a sepa-
rate database, merged with Ecuadorian data from the larger
trial, and analysed using the Statistical Package for the
Social Sciences v13.0 (SPSS, Chicago, IL, USA). Descriptive
statistics were calculated for maternal side effects and their
severity. An elevated body temperature measuring ‡40.0 C
or 38–39.9 C were classiﬁed as high or mild/moderate
fever, respectively. Comparisons between Ecuadorian
women with and without high fever were performed using
chi-square and Fisher’s exact tests. Subgroup analyses were
conducted to establish consistency of efﬁcacy and safety for
various subgroups or risk groups. Rates of high fever in
Ecuador were compared with reported rates from other
sites. Relative risk (RR) and 95% conﬁdence intervals were
calculated as appropriate.
Results
A total of 895 women received 800-micrograms of sublin-
gual misoprostol for the treatment of primary PPH. The
most prevalent side effects following misoprostol treatment
were shivering (42.6%; 381/895) and fever (34.1%; 305/
895). Reports of shivering, fever, and temperature of
‡40.0 C among women receiving misoprostol varied across
sites (Table 1). At the hospital in Ecuador, 35.6% (58/163)
of women receiving misoprostol had a fever of ‡40.0 C,
compared with reported rates that ranged from 0 to 9.5%
in the other eight hospitals. There were no reports of side
effects resulting in any prolonged hospital stay, and all
women with high fever made a full recovery.
Temperature trends were documented for the 58 cases of
high fever (‡40.0 C) in Quito, Ecuador. High fever was
typically characterised by a sharp increase in temperature
within 1 hour of treatment, a peak in temperature
1–2 hours post-treatment, and a gradual decline in temper-
ature over a period of 3 hours. Average temperatures
remained above 40.0 C for less than 2 hours, and measured
below 38.0 C approximately 6 hours after receiving
misoprostol (Figure 1). Temperature trends for mild/mod-
erate fevers followed a similar pattern, but with lower peak
temperatures (data not shown). Women with high fever
were treated with oral acetaminophen, cool compresses,
and aspirin delivered intravenously. Treatment practices
were similar for women with mild to moderate fevers,
although a subset of women with mild/moderate fevers did
not receive treatment with IV aspirin. An analysis of this
subset showed that cases of mild to moderate fevers treated
with IV aspirin resolved similarly to those that were treated
with only oral acetaminophen and/or cold compresses
(data not shown).
Table 1. Rates of shivering, fever, and temperature ‡40.0 C by site
following sublingual misoprostol for PPH treatment
Any
shivering
Any
fever
Fever
‡ ‡ 40.0 C
n/N % n/N % n/N %
Ecuador
Quito* 146/163 89.6 151/163 92.6 58/163 35.6
Burkina Faso
Bobo Dioulasso** 22/34 64.7 10/34 29.4 0/34 0.0
Egypt
Alexandria* 14/198 7.1 9/198 4.5 0/198 0.0
Cairo** 58/236 24.6 48/236 20.3 3/236 1.3
Turkey
Ankara** 25/33 75.8 14/33 42.4 1/33 3.0
Vietnam
Binh Duong* 31/53 58.5 15/53 28.3 1/53 1.9
Tu Du* 38/74 51.4 42/74 56.8 7/74 9.5
Cu Chi** 28/52 53.8 13/52 25.0 0/52 0.0
Hoc Mon** 19/52 36.5 3/52 5.8 1/52 1.9
*These sites participated in the PPH treatment trial conducted
among women not exposed to oxytocin during labour.
19
**These sites participated in the PPH treatment trial conducted
among women who received oxytocin prophylactically.
18
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receiving 800 micrograms of misoprostol sublingually expe-
rienced an elevated body temperature (‡38.0 C). Shivering
usually accompanied fever, irrespective of peak temperature
(89.6%; 146/163). Severe shivering (deﬁned as uncontrollable
shaking that made it difﬁcult to articulate or control physical
movement) was more frequently reported among women
with temperatures of ‡40.0 C (27.6%; 16/58) compared with
those without (2.9%; 3/105; RR 9.66; 95% CI 2.94–31.8).
Moderate shivering was described as producing strong trem-
bling that did not affect speech or mobility. High fevers were
often preceded by moderate or severe shivering within the
ﬁrst 20 minutes of receiving misoprostol [41.4% (24/58)
versus 13.3% of women who did not develop high fever
(14/105); RR 3.10; 95% CI 1.74–5.52]. Other known side
effects of misoprostol, such as nausea, vomiting, and diar-
rhoea, were infrequent, and rates did not vary by degree of
fever. Transient delirium or altered sensorium (such as dis-
orientation, confusion, decreased bilateral/blurry vision,
speech impairment, muscular stiffness, neuromotor agita-
tion, or hallucinations) was reported in eight women (8/58)
with high fever versus three women (3/93) who had mild/
moderate fever (RR 4.28; 95% CI 1.18–15.5).
Baseline characteristics were comparable among Ecuado-
rian women who did and did not develop a high fever,
except for previous PPH and rapid placental expulsion
(Table 2). Outcomes associated with postpartum blood loss
in Ecuador (i.e. efﬁcacy of initial uterotonic therapy, time
to control active bleeding, and total blood loss) did not
vary between women with high fever and those without,
demonstrating consistency in treatment outcomes among
subgroups. Recourse to additional interventions (including
blood transfusion, exploration under anaesthesia, and the
administration of additional uterotonics) was similar
among women with high fever and those without. Among
the women who were given additional uterotonics
(n = 12), rectal misoprostol (200 micrograms) was given to
one woman in the high fever group (1/4), and to one
woman in the no high fever group, who received
800 micrograms (1/8). 48.3% of women (28/58) who devel-
oped high fever were administered IV ﬂuids/electrolytes
following temperature elevation, compared with 35.2%
(37/105) of women without high fever (p = 0.072). Women
who developed high fever were as likely to be reported in
‘good’ condition at discharge as were those who did not
experience high fever.
On average, women were discharged from the hospital in
Ecuador approximately 27.4 (±9.9) hours following deliv-
ery, independent of the incidence of fever (P = 0.749). Exit
interviews were conducted immediately prior to discharge
for all women. Among those women who had fever of
‡40.0 C, one-third (18/58) did not report having experi-
enced this side effect; likewise, no provider reports of delir-
ium/altered sensorium or fainting were conﬁrmed by
women during the exit interviews. Nevertheless, 50.9% (55/
108) and 44.0% (44/100) of women who conﬁrmed pro-
vider reports of having experienced shivering and fever
during their exit interviews characterised them as being
‘intolerable’. Women who experienced high fevers were
more likely to report shivering as ‘intolerable’, compared
with women who did not develop high fever (RR 1.51;
Table 2. Characteristics of Ecuadorian population by incidence of
high fever following misoprostol treatment
Developed
high fever
n =5 8
No high
fever
n = 105
P
value
Age (years)
Younger than 20 17 (29.3) 32 (30.5) 0.076
20–34 40 (69.0) 61 (58.1)
35 or older 1 (1.7) 12 (11.4)
No. of previous live births
0 24 (41.4) 41 (39.0) 0.829
1–3 29 (50.0) 57 (54.3)
4+ 5 (8.6) 7 (6.7)
Pre-delivery haemoglobin
less than 11.5 g/dL
6 (10.3) 3 (2.9) 0.053
Gestational age (weeks)
Pre-term (less than 37) 1 (1.7) 5 (4.8) 0.241
Term (37.0–40.9) 47 (81.0) 90 (85.7)
Post-term (41 or more) 10 (17.2) 10 (9.5)
Known previous PPH 6 (10.3) 2 (1.9) 0.024
Multiple pregnancy 0 (0.0) 0 (0.0) –
Oxytocin given in third stage
of labour or earlier
0 (0.0) 0 (0.0) –
Epidural given 2 (3.4) 3 (2.9) 0.585
Suturing after delivery 39 (67.2) 79 (75.2) 0.274
Placental delivery
within 15 minutes
48 (82.8) 69 (65.7) 0.021
Blood loss (ml) at time of
treatment (median IQR)
850
(750–950)
850
(750–1000)
0.322
Numbers are n (%) unless otherwise speciﬁed.
36.0
37.0
38.0
39.0
40.0
41.0
42.0
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
012345678
B
o
d
y
 
t
e
m
p
e
r
a
t
u
r
e
 
(
C
e
l
s
i
u
s
)
M
i
s
o
p
r
o
s
t
o
l
 
p
l
a
s
m
a
 
l
e
v
e
l
s
 
(
n
g
)
Hours after sublingual  administration
Plasma Trend
Figure 1. Mean misoprostol plasma concentrations after sublingual
administration of misoprostol (800 micrograms),
23 and mean
temperatures of 58 cases of high fever over time.
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high fever were no more likely than those who experienced
mild/moderate fevers to report the fever itself as ‘intolera-
ble’ (RR 1.50; 95% CI 0.97–2.32).
Discussion
These results conﬁrm that women who receive misoprostol
postpartum are at risk for shivering and fever. As in previ-
ous studies, such effects were related, transient, self-limit-
ing, and did not result in additional health
complications.
1,10,13–15 Nevertheless, a striking ﬁnding was
the unexpected rate of high fever in Ecuador as compared
with other study sites, with over one-third of women trea-
ted with misoprostol developing a temperature of ‡40.0 C.
A comparison of the overall rates of shivering and fever
between sites shows that the thermoregulatory response to
misoprostol among Ecuadorian women is notably different
from women treated at the other sites (Table 1).
Prior to the present study, the detailed documentation of
fever characteristics, particularly fevers measuring ‡40.0 C,
has been scant.
12,15–17 The temperature trends recorded in
our study show misoprostol-induced fevers followed a
predictable pattern, and high fevers were often preceded by
moderate or severe shivering within the ﬁrst 20 minutes of
misoprostol administration. In contrast to the rapidly fatal,
irregular, uncontrolled spikes in temperature associated
with hyperthermia, high fever in Ecuador exhibited a
distinctive, consistent pattern: temperatures peaked approx-
imately 1.5 hours post-sublingual misoprostol administra-
tion, and decreased thereafter. As shown in Figure 1, the
pattern of temperature elevation mimics misoprostol blood
plasma concentration following sublingual administration.
23
The 30–60-minute lag between the peaks in plasma con-
centration and temperature may be attributable to the time
it takes for the febrile signal to be received and processed
in the hypothalamus, as well as for the physiological pro-
cesses associated with fever to elevate the body tempera-
ture.
24 These data suggest that the temperature elevation
associated with misoprostol use is dependent on plasma
concentrations, and explains why fever is dose- and route-
dependent.
5–7
The temperature elevations associated with misoprostol
are compatible with a shift in the hypothalamic set point,
and do not appear to be cases of hyperthermia, but rather
of pyrexia. Indeed, E-series prostaglandins (PGEs) are
involved in the endogenous fever mechanism, and prosta-
glandin E2 (PGE2) in particular is acknowledged as the pri-
mary mediator of fever induction
20 through an interaction
with the EP3 receptor.
25,26 However, there is no evidence
that prostaglandin E1 (PGE1), of which misoprostol is an
analogue, acts differently from PGE2:
20,27 in fact, the bio-
logically active form of misoprostol, misoprostol acid, has
been shown to bind to the EP3 receptor.
28 Considering this
evidence, we theorise that in the fever cases presented, mi-
soprostol may be mimicking endogenous PGEs in the ther-
moregulatory pathway by shifting the hypothalamic set
point upwards and stimulating temperature elevation. Fur-
ther pharmacologic studies are needed to validate this
hypothesis. Importantly, these fevers were well managed by
nurses with local treatment practices within the clinical
competencies of delivery attendants. Fevers followed a pre-
dictable course (Figure 1), and it is not clear if treatment
practices had any effect on fever resolution. Because antipy-
retics work by inhibiting endogenous prostaglandin pro-
duction,
24 the lack of treatment effect appears consistent
with fever resulting from exposure to exogenous prosta-
glandins.
Some researchers have suggested that the increased rate
of fever following postpartum misoprostol administration
may result from a lowered threshold for prostaglandin-
induced temperature elevation in term pregnant women.
29
However pre-clinical work suggests that, conversely, term
pregnancy naturally suppresses fever because of an increase
in the endogenous production of antipyretics and a
decrease in endogenous pyrogen formation.
30 Rates of fever
following misoprostol treatment in postpartum women at
term however, do seem to exceed rates in women given
similar doses earlier in gestation.
31
Despite the uncertain relationship between prostaglan-
dins, gestation, and fever, it is well known that endogenous
prostaglandins play a role in the physiological processes
involved in labour and delivery. Prostaglandins are pro-
duced by the intrauterine tissues and are involved in the
rupture of the membranes, cervical ripening, myometrial
contractility, placental separation, and uterine involu-
tion.
28,32 In fact, postpartum shivering is not uncommon,
33
and may be related to the release of prostaglandins at par-
turition. In the present study, high fever was more com-
mon among Ecuadorian women who experienced a rapid
expulsion of the placenta (Table 2). Because endogenous
prostaglandins are involved in placental separation,
32 the
concurrent ﬂood of both endogenous and exogenous pro-
staglandins may have increased the risk of shivering and
fever in Ecuador. Interestingly, placental size is typically
larger in high-altitude populations (a developmental
response to the hypoxic environment), and should be con-
sidered further by researchers studying these physiological
processes.
34
Few PPH studies testing oral or sublingual misoprostol
regimens have systematically measured body temperature at
predetermined time intervals following postpartum
use.
7,10,13,14,17,35 Some studies have documented the occur-
rence of fever based on routine temperature measurement at
1-hour postpartum; others have measured temperature only
after fever was reported by women or detected by attendants.
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fever in previously published studies, as well as in the study
sites discussed in this manuscript. The level of postpartum
monitoring may also lead to varying rates and/or under-
reporting of fever across hospitals participating in the same
protocol. Because the onset of moderate/severe shivering
and high fever following misoprostol administration for
PPH is visibly detectable by the delivery attendant within the
ﬁrst hour post-treatment, we do not believe that the differ-
ences in the reports of high fevers among hospitals are
attributable to variation in duration of hospital stay. Fur-
thermore, following the ﬁrst reports of elevated body tem-
perature in Quito, study teams at the other sites were alerted
to the possibility of such effects. Regular monitoring visits to
these sites conﬁrmed that the occurrence of shivering, fever,
and temperatures of ‡40.0 C remained consistent at all sites
for the duration of the study. Efforts to call the study team’s
attention to the possibility of these effects did not result in
increasing reports of high fevers.
It is unclear why women in Quito demonstrated
uncharacteristically high rates of fever following postpar-
tum administration of misoprostol. Following the ﬁrst
reports of high fever, the study team in Ecuador reviewed
both their clinical practices and the patient characteristics
that could possibly contribute to the increased rate of
high fevers. Patterns or associations with other medica-
tions taken and/or other health conditions were explored,
and none were identiﬁed. At study completion, the treat-
ment arms were unmasked, revealing that high fever only
occurred among women treated with misoprostol; no
cases with high fever were documented in the oxytocin
group in any study site. The occurrence of high fevers
was also found to be evenly distributed over the course of
the study, and not clustered around a speciﬁc time frame,
which might have indicated a problem with infection in
the labour or delivery ward, or with the study supplies.
Given that high fever only occurred among women trea-
ted with misoprostol, was short-lived, and was not treated
with antibiotics, infection is not suspected to be the
cause.
Environmental factors such as Quito’s high elevation as
well as genetic factors were also explored. It may be that a
genetic variation permits misoprostol, a PGE1 analogue, to
activate the endogenous fever mechanism that is typically
triggered by PGE2. If this is the case, the high rate of fever
among Ecuadorian women may represent a high frequency
of a variant allele in this homogenous population. The
potential role of altitude on fever incidence also remains
speculative. In fact, there have been no reports to date of
high fevers occurring after misoprostol administration in
the puerperium in other high-elevation settings.
36,37 Other
environmental factors such as the ambient temperature in
Quito are not suspected to have contributed to the rate of
high fevers. Because of its elevation and its proximity to
the equator, Quito has a fairly constant cool climate, with
an average year-round temperature of 19 C (66 F).
Importantly, the participant population in Quito was
highly homogenous; therefore, the incidence, treatment,
and cause of the high fevers presented in this paper may
have limited generalisability to other populations. Apart
from the study sites discussed in this paper, it is not known
whether other populations will also experience similar rates
of high fever.
Although there are many questions that remain about
the incidence of high fever in Ecuador, our ﬁndings con-
cur with previous experience and research that have
shown the side effects following misoprostol administra-
tion not to be life-threatening.
1,10,38 Fever is commonly
observed when misoprostol is given for a range of health
indications. The temperature trends documented in this
study provide reassurance to clinicians that misoprostol-
induced fevers (regardless of how high the peak tempera-
ture) are transitory. Lower dosages or different routes of
administration may minimise the occurrence of such
events.
3,6 Currently, however, no data support other routes
of administration or lower doses of misoprostol as a ﬁrst-
line treatment for PPH.
2,18,19 Furthermore, we do not
know if treatment affects the course of misoprostol-
induced fevers: the cases of fever presented in this paper
followed a predictable pattern seemingly independent of
the type of management. Nevertheless, providers should be
informed of what to expect regarding body temperature
elevation, shivering and other side effects following post-
partum misoprostol administration, and should be advised
of acceptable treatment and palliative measures.
Until deﬁnitive relationships between genetic or environ-
mental variation and drug response can be established, the
questions of why some women develop high body tempera-
ture, and why so many high fevers occurred in Ecuador,
remain. The recent burgeoning of pharmacogenetic studies
may shed light on these hypotheses.
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